Neuphoria Therapeutics (NEUP) EBITDA Margin (2024 - 2025)

Neuphoria Therapeutics (NEUP) posted quarterly EBITDA Margin of 43981.65% for Q2 2025, up 54981.75% quarter-over-quarter from 79.85% in Q1 2025.

Neuphoria Therapeutics (NEUP) EBITDA Margin (2024 - 2025) Analysis & Trends

Neuphoria Therapeutics (NEUP) has reported EBITDA Margin for 2 consecutive years, with 43981.65% the latest figure, recorded in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	138.83 Bn	130.98 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	85.79 Bn	77.79 Bn	3.93 Bn	30.15%
3	Argenx Se	64.95 Bn	59.77 Bn	1.37 Bn	32.54%
4	Moderna	58.59 Bn	53.46 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.93 Bn	36.83 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.52 Bn	28.21 Bn	992.69 Mn	17.93%
7	BioNTech SE	27.98 Bn	9.58 Bn	668.28 Mn	-35.57%
8	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	19.75%
10	Neuphoria Therapeutics	21.37 Mn	1.93 Mn	-	-

Download Data